ALK and lung adenocarcinoma: Herein, we present a case of unresectable locally advanced lung adenocarcinoma harboring a novel MIR217HG-ALK rearrangement, and after receiving neoadjuvant treatment with alectinib, the patient achieved major pathological response (MPR) and demonstrated disease-free survival (DFS) exceeding 19 months without notable adverse reactions observed.